Analyst Ratings For CymaBay Therapeutics (NASDAQ:CBAY)
Today, Piper Jaffray Companies reiterated its Buy rating on CymaBay Therapeutics (NASDAQ:CBAY) with a price target of $12.00.
There are 9 buy ratings on the stock.
The current consensus rating on CymaBay Therapeutics (NASDAQ:CBAY) is Buy (Score: 3.00) with a consensus target price of $14.00 per share, a potential 55.04% upside.
Some recent analyst ratings include
- 10/27/2017-Piper Jaffray Companies Reiterated Rating of Buy.
- 9/26/2017-Cantor Fitzgerald Reiterated Rating of Buy.
- 8/23/2017-Leerink Swann initiated coverage with a Outperform rating.
- 8/18/2017-SunTrust Banks, Inc. initiated coverage with a Buy rating.
- 8/11/2017-Ifs Securities was Downgraded by analysts at Ifs Securities from a “Strong-Buy ” rating to a ” Outperform” rating.
- 7/20/2017-CIBC Reiterated Rating of Outperform .
Recent Insider Trading Activity For CymaBay Therapeutics (NASDAQ:CBAY)
CymaBay Therapeutics (NASDAQ:CBAY) has insider ownership of 15.10% and institutional ownership of 25.92%.
- On 10/3/2017 Kurt Von Emster, Director, sold 108,876 with an average share price of $7.85 per share and the total transaction amounting to $854,676.60. View SEC Filing
- On 9/29/2017 Kurt Von Emster, Director, sold 211,124 with an average share price of $8.09 per share and the total transaction amounting to $1,707,993.16. View SEC Filing
- On 8/1/2017 Robert James Wills, Director, bought 5,000 with an average share price of $6.84 per share and the total transaction amounting to $34,200.00. View SEC Filing
- On 7/20/2017 Charles Mcwherter, SVP, bought 5,000 with an average share price of $7.43 per share and the total transaction amounting to $37,150.00. View SEC Filing
- On 7/20/2017 Sujal Shah, Insider, bought 10,000 with an average share price of $7.34 per share and the total transaction amounting to $73,400.00. View SEC Filing
- On 9/6/2016 Robert James Wills, Director, bought 25,000 with an average share price of $2.43 per share and the total transaction amounting to $60,750.00. View SEC Filing
- On 4/15/2016 Charles Mcwherter, VP, bought 3,000 with an average share price of $1.68 per share and the total transaction amounting to $5,040.00. View SEC Filing
Recent Trading Activity for CymaBay Therapeutics (NASDAQ:CBAY)
Shares of CymaBay Therapeutics closed the previous trading session at with shares trading hands.